Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00351624 · ClinicalTrials.gov registry record · Phase 3
Effects of Docosahexaenoic Acid (DHA) on Cognitive Function in Children 4 Years of Age
A Phase 3 study, sponsored by dsm-firmenich Switzerland.
- Completed
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
NCT00351624 is a Phase 3 study that has completed, run by dsm-firmenich Switzerland. The registered enrollment target is 216 participants.
The verdict
NCT00351624, a Phase 3 study, has completed, sponsored by dsm-firmenich Switzerland.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether a 4-month period of supplementation with 400 mg/day of docosahexaenoic acid (DHA) provided from chewable softgel capsules containing bubblegum flavored microalgal oil (DHASCO-S) versus placebo improves one or more cognitive measures of attention, memory, processing speed, and error rate in healthy children 4 years of age. The secondary objectives are to measure the safety and tolerability of the DHA dose administered and to measure blood DHA levels before and after supplementation.
Interventions
- BEHAVIORAL placebo
- BEHAVIORAL DHA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00351624
The ClinicalTrials.gov registry entry for NCT00351624 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is dsm-firmenich Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00351624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00351624 about?
NCT00351624 is a clinical study titled "Effects of Docosahexaenoic Acid (DHA) on Cognitive Function in Children 4 Years of Age". The primary objective of this study is to determine whether a 4-month period of supplementation with 400 mg/day of docosahexaenoic acid (DHA) provided from chewable softgel capsules containing bubblegum flavored microalgal oil (DHASCO-S) versus placebo improves one or more cognitive measures of atte...
What is the current status of trial NCT00351624?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2006-05. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00351624?
The interventions under investigation include: placebo (BEHAVIORAL), DHA (BEHAVIORAL).
Who is sponsoring clinical trial NCT00351624?
This trial is sponsored by dsm-firmenich Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.